Clinical Trial Update: A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil [Phase 3]

View source ↗

Summary

Phase 3 trial of oral upadacitinib for moderate to severe atopic dermatitis in Brazil has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis (AD) | Phase 3 | Status: WITHDRAWN